Latest Tempus News & Updates

See the latest news and media coverage for Tempus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tempus

AI-enabled precision medicine platform

tempus.com

Headquarters: Chicago, United States
Founded year: 2015
Company type: Public company
Number of employees: 3,000–5,000
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Tempus

In short: Tempus agreed to acquire Personalis for $1.5 billion and secured FDA approval for its xT CDx assay, significantly expanding its AI platform.

Company announcements

July 30 Tempus

Tempus reports second quarter 2026 results

Total revenue grew 22% year-over-year to $382.5 million, and the company announced an agreement to acquire Personalis.

July 29 Tempus

Tempus validates AI-enabled ECG model for 1-year AF risk

The model predicts risk of atrial fibrillation or flutter within one year using electrocardiogram data, validated across multiple centers for early detection.

July 22 Tempus

Tempus announces national launch of OneOme pharmacogenomics testing

The testing provides genetic insights to optimize medication safety and dosing, bridging tumor profiling and drug processing.

July 20 Tempus

Tempus to acquire Personalis for $1.5 billion

The acquisition integrates MRD technology into Tempus' AI platform to advance cancer monitoring.

Media coverage

July 31 GenomeWeb

Tempus AI Q2 Revenue Boost Driven by Growth in Oncology Testing With Long-Term...

Revenue growth of 31 percent in the firm's oncology business was responsible for the bulk of the quarter's 22 percent year-over-year revenue hike.

July 31 Yahoo Finance

Tempus AI Q2 Earnings Call Highlights

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and...

July 30 GuruFocus

Tempus AI (TEM) Q2 2026 Results Highlight Growth Potential Despi

On July 30, 2026, Tempus AI Inc (NASDAQ: TEM) reported strong Q2 revenue growth and key FDA...

July 30 GuruFocus

Tempus AI (TEM) Revises 2026 EBITDA Outlook Amid Mixed Market Si

On July 30, 2026, Tempus AI Inc (NASDAQ: TEM) updated its financial guidance for fiscal year 2026,...

Never miss news about Tempus

Track Tempus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tempus competitors & trending companies

Browse news for competitors to Tempus and other trending companies.